CoChat

Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination

Open access
Bol, Kalijn F, Aarntzen, Erik H J G, Hout, Florentien E M in 't, Schreibelt, Gerty, Creemers, Jeroen H A, Lesterhuis, W Joost, Gerritsen, Winald R, Grunhagen, Dirk J, Verhoef, Cornelis, Punt, Cornelis J A, Bonenkamp, Johannes J, de Wilt, Johannes H W, Figdor, Carl G, de Vries, I Jolanda M · 2016 · OncoImmunology
Cited by 72

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Melanoma patients with regional metastatic disease are at high risk for recurrence and metastatic disease, despite radical lymph node dissection (RLND). We investigated the immunologic response and clinical outcome to adjuvant dendritic cell (DC) vaccination in melanoma patients with regional metastatic disease who underwent RLND with curative intent. In this retrospective study, 78 melanoma patients with regional lymph node metastasis who underwent RLND received autologous DCs loaded with gp100 and tyrosinase and were analyzed for functional tumor-specific T cell responses in skin-test infiltrating lymphocytes. The study shows that adjuvant DC vaccination in melanoma patients with regional lymph node metastasis is safe and induced functional tumor-specific T cell responses in 71% of the patients. The presence of functional tumor-specific T cells was correlated with a better 2-year overall survival (OS) rate. OS was significantly higher after adjuvant DC vaccination compared to 209 matched controls who underwent RLND without adjuvant DC vaccination, 63.6 mo vs. 31.0 mo (p = 0.018; hazard ratio 0.59; 95%CI 0.42–0.84). Five-year survival rate increased from 38% to 53% (p < 0.01). In summary, in melanoma patients with regional metastatic disease, who are at high risk for recurrence and metastatic disease after RLND, adjuvant DC vaccination is well tolerated. It induced functional tumor-specific immune responses in the majority of patients and these were related to clinical outcome. OS was significantly higher compared to matched controls. A randomized clinical trial is needed to prospectively validate the efficacy of DC vaccination in the adjuvant setting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2015.1057673

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 72

Metadata

Authors
Bol, K. F., Aarntzen, E. H. J. G., Hout, F. E. M. I. '., Schreibelt, G., Creemers, J. H. A., Lesterhuis, W. J., Gerritsen, W. R., Grunhagen, D. J., Verhoef, C., Punt, C. J. A., Bonenkamp, J. J., de Wilt, J. H. W., Figdor, C. G., & de Vries, I. J. M.
Venue
OncoImmunology
Published
2015-06-05
Volume
5
Issue
1
Pages
e1057673
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W2175588819
Cited by
72
References
2
FWCI
3.71
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. https://app.cochat.ai/papers/10.1080/2162402x.2015.1057673
The paper
Bol, K. F., Aarntzen, E. H. J. G., Hout, F. E. M. I. '., Schreibelt, G., Creemers, J. H. A., Lesterhuis, W. J., Gerritsen, W. R., Grunhagen, D. J., Verhoef, C., Punt, C. J. A., Bonenkamp, J. J., de Wilt, J. H. W., Figdor, C. G., & de Vries, I. J. M. (2016). Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. OncoImmunology. https://doi.org/10.1080/2162402x.2015.1057673

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.